Stocks and Investing Stocks and Investing
Tue, January 4, 2022
Mon, January 3, 2022
Sun, January 2, 2022
Fri, December 31, 2021
Thu, December 30, 2021
Wed, December 29, 2021
Tue, December 28, 2021
Mon, December 27, 2021
Thu, December 23, 2021
Wed, December 22, 2021
Tue, December 21, 2021

Steve Valiquette Maintained (AMED) at Buy with Decreased Target to $213 on, Dec 21st, 2021


Published on 2024-10-27 19:04:36 - WOPRAI, Steve Valiquette
  Print publication without navigation


Steve Valiquette of Barclays, Maintained "Amedisys, Inc." (AMED) at Buy with Decreased Target from $236 to $213 on, Dec 21st, 2021.

Steve has made no other calls on AMED in the last 4 months.



There are 9 other peers that have a rating on AMED. Out of the 9 peers that are also analyzing AMED, 3 agree with Steve's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Scott Fidel of "Stephens & Co." Maintained at Hold with Increased Target to $185 on, Thursday, November 4th, 2021
  • Whit Mayo of "SVB Leerink" Maintained at Hold with Increased Target to $181 on, Thursday, November 4th, 2021
  • Gary Taylor of "Cowen & Co." Initiated at Hold and Held Target at $195 on, Friday, September 10th, 2021


These are the ratings of the 6 analyists that currently disagree with Steve


  • John Ransom of "Raymond James" Maintained at Buy with Decreased Target to $225 on, Monday, November 8th, 2021
  • Jonathan Yong of "Credit Suisse" Maintained at Buy with Increased Target to $205 on, Thursday, November 4th, 2021
  • Frank Morgan of "RBC Capital" Maintained at Buy with Decreased Target to $221 on, Thursday, November 4th, 2021
  • Michael Wiederhorn of "Oppenheimer" Maintained at Buy with Decreased Target to $225 on, Wednesday, November 3rd, 2021
  • David Macdonald of "Truist Securities" Maintained at Strong Buy with Decreased Target to $190 on, Wednesday, October 13th, 2021
  • Andrew Mok of "UBS" Initiated at Strong Sell and Held Target at $150 on, Friday, September 24th, 2021